Treatment of age-related memory complaints with Ginkgo biloba extract: A randomized double blind placebo-controlled study

Phytomedicine

Volumn 5, Issue 6, 1998, Pages 425-434

  Brautigam, M R H ^a,g   Blommaert, F A ^b,g   Verleye, G ^c   Castermans, J ^d   Steur, E N H Jansen ^e   Kleijnen, J ^f  

^a Arbogroep GAK   (Netherlands)

^b Biohorma BV   (Netherlands)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d Psychological Consultancy   (Belgium)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f UNIVERSITY OF YORK   (United Kingdom)

^g NONE   (Netherlands)

Author keywords

Age related memory complaints; Ginkgo biloba; Randomized double blind placebo controlled study

Indexed keywords

EID: 0000441972     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0944-7113(98)80038-X     Document Type: Article

References (38)

1. Anadere, I., Chmiel, H., Witte, S.: Hemorheological findings in patients with completed stroke and the influence of a Ginkgo biloba extract. Clin. Hemorheol 5: 411-20, 1985.
2. Arenberg. D.: Differences and changes with age in the Benton Visual Retention Test. J. Gerontol., 33 (4): 534-540, 1978.
3. Artmann, G. M., Schikarski, C.: Ginkgo biloba extract (Egb 761) protects red blood cells from oxidative damage. Clin. Hemorheol., 13 (4): 529-39, 1993.
4. Baddeley, A. D., Wilson, B. A., Watts, F. N.: Handbook of memory disorders. MRC applied psychology unit, Cambridge, UK, 1995.
5. Baranes, J., Hellegouarch, A., Le Hegarat, M., Viossat, I., Auget, M., Chabrier, P. E. F. and Braquet, P.: The effect of paf-acether on the cardiovascular system and their inhibition by new highly specific paf-acether receptor antagonist BN 52021. Pharmacol. Res. Commun., 18 (8): 717-37, 1986.
6. Beck, A. T., Beamesderfer, A.: Assessment of depression: the depression inventory. Psychological Measurements in Psychopharmacology. Mod. Probl. Pharmacopsychiatry, 7: 151-69, ed Pichot P, Paris (Karcher, Basel 1974).
7. Benton, A. L., Eslinger, P. J., Damasio, A. R.: Normative observations on neuropsychological test performances in old age. J. Clin. Neuropsychol., 3 (1): 33-42, 1981.
8. Benton, A. L.: Revised visual retention test (4th ed.) New York: Psychological Corporation, 1974.
9. Borzeix, M. G., Labos, M., Hartl, C.: Recherches sur l'action antiagregante de l'extrait de Ginkgo biloba. Sem. Hop. Paris 56, 7-8: 393-8, 1980.
10. Braquet, P.: Ginkgolides. Chemistry, biology, pharmacology and clinical perspectives. Barcelona: JR Prous Science Publishers, 1988.
11. Chatterjee, S. S., Gabard, B.: Studies on the mechanism of action of an extract of Ginkgo biloba, a drug used for treatment of ischaemic vascular diseases. Naunyn Schmiedebergs Arch. Pharmacol. 321 (suppl.) a, 1982a.
12. Chatterjee, S. S., Gabard, B.: Protection of doxorubicin toxicity by an extract of Ginkgo biloba Naunyn Schmiedebergs Arch. Pharmacol. 319 (suppl) b, 1982b.
13. Chung, K. F., McCuster, M., Page, C. P., Dent, G., Guinot, Ph., Barnes, P. J.: Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet, January 31: 248-50, 1987.
14. Cohen, R. J., Montaque, P., Nathanson, L. S., Swerdlik, M. E.: Psychological Testing. An introduction to Tests & Measurement. Mayfield Publishing Company Mountain Vieuw, California, 1988.
15. Etienne, A., Baranas, J., Hecquet, F., Hellegouarch, A., Clostre, F.: Effet stabilisateur de membrane d'un extrait de Ginkgo biloba. Planta, med. 39 (3): 237, 1980.
16. Folstein, M. F., Folstein, D. E., McHugh, P. R.: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res., 12: 189-98, 1975.
17. Guinot, P., Caffrey, E., Lambe, R., Darragh, A.: Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis 19: 219-23, 1989.
18. Holzl, J.: Inhaltstoffe von Ginkgo biloba. Pharm. Unserer Zeit 21 (5): 215-23, 1992.
19. Jolles, J., Verhey, F. R. J., Riedel, W. J., Houx, P. J.: Cognitive impairment in elderly people: predisposing factors and implications for experimental drug studies. Drugs Aging 7 (6): 459-79, 1995.
20. Jung, F., Mrowietz, C., Kiesewetter, H., Wenzel, E.: Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittel-Forsch. 40: 589-93, 1990.
21. Karcher, L., et al.: Protective effect of an extract of Ginkgo biloba on brain energy metabolism in hypoxia and ischaemia. Cerebral ischaemia, meeting Toulouse, 3.-4. 11. 1983.
22. Kleijnen, J., Knipschild, P.: Ginkgo biloba. Lancet, 340: 1136-39, 1992.
23. Kleijnen, J.: Food supplements and their efficacy. Thesis Maastricht, 1991.
24. Krieglstein, J.: Neuroprotective properties of Ginkgo biloba constituents. Z. Phytotherapie 15: 92-6, 1994.
25. Lindeboom, I., Koene, T., Matto, D.: The diagnostic value of tests for mental control. Tijdschr. Gerontol. Geriatr., 24 (3): 105-09, 1993.
26. Lindsberg, P. J., Hallenbeck, J. M., Feuerstein, G.: Platelet-activating factor in stroke en brain injury. Ann. Neural., 30: 117-29, 1991.
27. Mormont, C.: The influence of age and depression on intellectual and memory performances. Acta Psychiat. Belg., 2: 127-34, 1984.
28. Nunez, D., Chignard, M., Korth, R., le Cavectic, J. P., Norel, X., Spinnewijn, B., Braquet, P., Benveniste, J.: Specific inhiblition of paf-acether-induced platelet inhibitors kadsurenone and CV 3988. Eur. J. Pharmacol., 123; 197-205, 1986.
29. Oberpichler, H., Sauer, D., Rossberg, C., Mennel, H. D., Krieglstein, J.: PAF antagonist Ginkgolide B reduces postischemic neuronal damage in rat brain hippocampus. J. Cereb. Blood Flow metabol., 10: 133-5, 1990.
30. Reuter, H. D.: Ginkgo biloba-Botany, constituents, pharmacology and clinical trials. Br. J. Phytotherapy 4 (1): 3-20, 1995/96.
31. Schofield, P. W., Jacobs, D., Marder, K., Sano, M., Stern, Y.: The validity of new memory complaints in the elderly. Arch. Neurol., 54: 756-59, 1995.
32. Schofield, P. W., Marder, K., Dooneief, G., Jacobs, D., Sano, M., Stern, Y.: Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. Am. J. Psychiatry, 154 (5): 609-15, 1997.
33. Statistica 5.0 1995, Statsoft, Inc. 2300 E. 14th St. Tulsa, OK 74104 USA, 1995.
34. Sticher, O., Hasle, A., Meier, B.: Ginkgo biloba - Eine Standortbestimmung. Dtsch. Apoth. Ztg., 36: 827-35, 1991.
35. Tamkin, A. S., Kunce, J. T.: A comparison of three neuropsychological tests: the Weigl, Hooper, and Benton. J. Clin. Psychol., 41 (5): 660-4, 1985.
36. Tea, S., Celsis, P., Clanet, M., Marc-Vergnes, J. P.: Effects clinique, hemodynamique et metabolique de l'extrait de Ginkgo biloba en pathologie vasculaire cerebrale. Gazette Medicale de France 86: 4149-52, 1979.
37. Wesnes, K., Simmons, D., Rook, M., Simpson, P.: A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Hum. Psychopharmacol., 2: 159-69, 1987.
38. Witte, S., Anadere, I., Chmiel, H.: Therapeutical effect of Ginkgo biloba flavon glucosides on increased viscoelasticity of blood. Rev. Port. Hemorreol., 2 (1): 5-12, 1988.